| Autor: |
K, Hoogenberg, J, van der Tuin |
| Jazyk: |
Dutch; Flemish |
| Rok vydání: |
2002 |
| Předmět: |
|
| Zdroj: |
Nederlands tijdschrift voor geneeskunde. 146(44) |
| ISSN: |
0028-2162 |
| Popis: |
A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus. No long-term randomised clinical trials have examined the cardiovascular outcomes of the alpha-adrenergic blockers to which doxazosin belongs. The drug was removed from the largest study into blood pressure and cholesterol reduction ever performed until now (the antihypertensive and lipid-lowering treatment to prevent heart attack trial), due to an increased incidence of cardiovascular events and in particular congestive heart failure. The clinical significance of its insulin-sensitivity improving and lipid-neutralising effects in small-scale, short-term, small patient-group studies are ambiguous. Accordingly, national and international guidelines omitted the drug in their treatment recommendations. The advertisement claims are therefore misleading. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
